References
- American Cancer Society. Cancer Facts & Figures 2012. American Cancer Society, Atlanta, USA (2012).
- Sing A, Freudenberg N, Kortsik C et al. Comparison of the sensitivity of sputum and brush cytology in the diagnosis of lung carcinomas. Acta Cytol. 41(2), 399–408 (1997).
- Frost JK, Ball WC Jr, Levin ML et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am. Rev. Respir. Dis. 130, 549–554 (1984).
- Van de Kant KDG, van der Sande LJTM, Jöbsis Q et al. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir. Res. 13, 117 (2012).
- Horvath I, Lazar Z, Giulai N et al. Exhaled biomarkers in lung cancer. Eur. Respir. J. 34, 261–275 (2009).
- Van Berkel JJBN, Dallinga JW, Möller GM et al. Development of accurate classification method based on the analysis of volatile organic compounds from human exhaled air. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 861, 101–107 (2008).
- Hu YJ, Qiu YH, Chen EG et al. Determination of volatile organic compounds in lung cancer cell lines and lung tissue. Zhejiang Da Xue Bao Yi Xue Ban 39(3), 278–84 (2010).
- Sponring A, Filipac W, Mikowini T et al. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 29, 419–426 (2009).
- Mochalski P, Sponring A, King J et al. Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro. Cancer Cell Int. 13, 72 (2013).
- Haselbag S, Fleuren GJ, Baelde JJ et al. Cytokine profile of cervical cancer cells, Gynocol. Oncol. 83(2), 235–243 (2001).
- Yamamoto T, Kimura T, Ueta E et al. Characteristic cytokine patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns. Oncology 64(4), 407–415 (2003).
- Bhatanagar S, Kumar A. The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr. Mol. Med. 12(1), 3–13 (2012).
- Poli D, Carbogniani P, Corradi M et al. Exhaled volatile organic compound in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir. Res. 6, 71 (2005).
- Poli D, Goldoni M, Caglieri A. Breath analysis in non-small cell lung cancer patients after surgical tumour resection. Acta. Biomed. 79( Suppl. 1), 64–72 (2008).
- Phillips M, Cataneo RN, Cummin ARC et al. Detection of lung cancer with volatile markers in the breath. Chest 123(6), 2115 (2003).
- Gardner JW, Bartlett PN. Electronic noses. Principles and applications. Meas. Sci. Technol. 11, 1087 (2000).
- Mazzone PJ, Wang XF, Xu Y. Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J. Thorac. Oncol. 7(1), 137–142 (2012).
- Machado RF, Laskowski D, Deffenderfer O et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am. J. Respir. Crit. Care Med. 171, 1286–1291 (2005).
- Dragonieri S, Annemaa JT, Schot R et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 64, 166–170 (2009).
- Dragonieri S, van der Scheeb MP, Massaroc T et al. An electronic nose distinguishes exhaled breath of patients with malignant pleural mesothelioma from controls. Lung Cancer 75, 326–331 (2012).
- Peng G, Hakim M, Broza YY et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br. J. Cancer 103, 542–551 (2010).
- Strazda G, Bukovskis M, Kopeika U et al. Analysis of exhaled breath with electronic nose and discrimination of lung cancer and COPD by logistic regression analysis. European Respiratory Society. Barcelona, Spain, 7–11 September 2013 (Poster 2891).
- Basanta M, Ibrahim B, Dockry R et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. Respir. Res. 23(13), 72 (2012).